Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

In a study by Gare et al. [7] a total of 66 patients with chronic renal failure and/or diabetes mellitus received low-dose dopamine (2 µg/kg/min) plus saline or saline alone for 48 hours.